Moderna shares fell 7% to $135.22 following a sharp rise to a record $176.66, as traders took profits after a 392% gain year-to-date. The pullback is orderly with no new company updates; the recent rally was driven by positive phase 3 melanoma trial data for its mRNA-based cancer therapy combined with Merck's Keytruda. Investors should watch for further price moves near $130 and upcoming data from Moderna's oncology pipeline, while being cautious due to the stock's volatility and ongoing losses.
Merck shares have risen 45% year-to-date, driven by strong sales of its KEYTRUDA drug and upcoming regulatory milestones. Between September and October, Merck faces several FDA decision deadlines for new drug applications, including WINREVAIR and WEL...
Moderna's stock jumped 11% with no new company news, driven by strong retail sentiment and trading momentum rather than fundamentals. Meanwhile, BioNTech rose only 2%, lagging behind both Moderna and the broader biotech sector, highlighting a growing...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
